Cor­cept shares soar af­ter Phase 3 win in plat­inum-re­sis­tant ovar­i­an can­cer

Cor­cept Ther­a­peu­tics’ oral glu­co­cor­ti­coid re­cep­tor an­tag­o­nist has im­proved sur­vival out­comes in a late-stage test in pa­tients with a chal­leng­ing form of ovar­i­an can­cer, send­ing its …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER